Objective: The types of post-transplantation malignancies may vary among different geographic regions and ethnic populations. The aim of the present study was to determine the risk and incidence of de novo carcinomas, clinical characteristics, and outcomes in renal transplant recipients (RTRs) who are followed up in our center and if there is an accumulation of one type of malignity and to examine screening procedures and frequency.
INTRODUCTION
Renal transplantation is considered as the best treatment choice of end-stage renal disease. However, renal transplantation has its own long-term complications. Renal transplant recipients (RTRs) are thought to have a higher risk of malignancy than the general population. [1] [2] [3] Post-transplantation malignancies remain one of the major causes of mortality among RTRs and are anticipated to be the leading cause of death within the next 20 years. [4] This risk is mainly attributed to the use of immune suppressive therapies during both induction and maintenance phases. The types of post-transplantation malignancies may vary among different geographic regions and ethnic populations. [5] The aim of the present study was to determine the risk and incidence of de novo carcinomas, clinical characteristics, and outcomes in RTRs who are followed up in our center.
MATERIAL AND METHODS
The files of 322 RTRs who were transplanted between January 1, 2005 and December 31, 2016 at the Nephrology Clinic were screened retrospectively.
After patients with graft removal (n=4) and who died (n=9) in this period were excluded, we analyzed 313 patients' data.
The immunosuppressive protocol consisted of induction therapy and standard maintenance immunosuppressive triple therapy.
Induction therapy consisted of basiliximab (chimeric monoclonal antibody against interleukin 2), anti-thymocyte globulin (ATG), and methylprednisolone based on individual immunologic risk. Maintenance treatment comprised calcineurin inhibitors (CNIs; cyclosporine A or tacrolimus) or inhibitors of mammalian target of sirolimus (sirolimus or everolimus), mycophenolate mofetil, and prednisolone.
A thorough pretransplant screening was conducted for occult malignancy, including chest X-ray, thoracic computed tomography if needed, breast and abdominal sonography, urinalysis, fecal occult blood testing, screening for nasopharyngeal carcinoma, Pap smear, serum alpha-fetoprotein (AFP), and prostate-specific antigen (PSA) level.
All patients with chronic hepatitis B or C received antiviral therapy and achieved sustained acceptable viral response before renal transplantation.
In the follow-up period, observation of microscopic or gross hematuria is verified with cystoscopy.
In addition, annual breast sonography and gynecologic examination for female RTRs and testing for serum PSA level for male RTRs are arranged. Patients with pretransplant native kidney cysts were checked by annual ultrasonography after renal transplantation.
For patients with hepatitis B or C virus infection, AFP and liver sonography are checked every 3 months. [6] Patients with malignancy developed no immunosuppressive treatment prior to renal transplantation.
Data collection
The main collected data included the date of transplantation, patients' age, gender, date of the last follow-up, cancer diagnosis, how many years after renal transplantation cancer develops, and the induction and management therapies they received were recorded.
Additional data for risk factor evaluation were also collected as follows: reason for transplantation, duration and type of dialysis, donor type (deceased or living), induction and maintenance immunotherapy regimen at discharge, and allograft lifetime.
Statistical analysis
Descriptive statistics were performed for all data. Results were presented as mean±SD for normally distributed data and as median (min-max) for dispersed data.
RESULTS
De novo malignancy was identified in eight patients (M/ F=7/1). The mean age of patients with malignancy was 54.87±12.5 years, and the median duration of dialysis was 44 (2-107) months. The average time from transplantation to tumor development was 50 (7-93) months.
Malignity development rate was found to be 2.5% among all RTRs. Five patients with malignancy were transplanted from living related donors, and three were from cadaveric source.
We determined that all of the patients with malignity received ATG as induction therapy, six patients were treated with tacrolimus, mycophenolate mofetil, and prednisolone as maintenance treatment, and in two patients, sirolimus was preferred instead of CNI because the primary renal failure etiology was polycystic renal disease (Table 1) .
Two patients had skin carcinoma, whereas renal cell carcinoma (RCC), hepatocellular carcinoma, thyroid papillary carcinoma, vulvar carcinoma, prostate carcinoma, and gastrointestinal stromal tumor were found in each other.
As soon as malignancy was diagnosed, immunosuppressive treatments were reduced, and patients were followed up closely for possibility of rejection.
Patients with skin carcinoma were excised locally, and surgical cure was provided. Patients were followed up closely.
The patient with thyroid papillary carcinoma underwent subtotal thyroidectomy and received radioactive iodine treatment, and no recurrence was observed.
The patient who had diagnosed native kidney with RCC underwent left nephrectomy. Further imaging studies were conducted to detect distant metastasis and followed up with no distant metastasis and recurrence.
The patient with gastrointestinal stromal tumor was started on imatinib mesylate treatment by the oncology department, and no recurrence was observed until today.
The patient with vulvar carcinoma was operated, surgical cure was provided, and distant metastasis was not detected.
The patient with hepatocellular carcinoma developed from hepatitis B had lamivudine prophylaxis. Tumor excision was performed, and there was no distant metastasis.
The patient with prostate adenocarcinoma did not accept operation or radiotherapy and was given only chemotherapy. He is currently followed up by the oncology department (Table 2 ).
DISCUSSION
The risk of developing cancer after renal transplantation is one of the important factors affecting long-term survival in transplant patients, and it is currently considered as the third largest cause of death in renal transplant patients. [7] The risk of developing cancer after renal transplantation appears to be at least three times higher in transplant patients than in dialysis patients. [8] In our study, the average time between renal transplantation and tumor development was 50 months. In the study by Li et al., [5] the duration between renal transplantation and tumor development was found to be 56 months.
The rate of cancer development after renal transplantation is between 4% and 18%. In the Republic of China, this rate has been reported as 0.56%-4.2%. [9] In the study by Elserwy et al., [10] patients with renal transplantation were investigated with regard to malignancy development in 36 years. The incidence of malignancy was found to be 4%, and the average time of development was found to be 35 months.
In the study by Zilinska et al., [11] in 1421 patients who underwent renal transplantation, the rate of malignity development was 6%, and the average time of malignity development was 45 months.
In the present study, we found that the overall prevalence of post-transplantation malignancy was 2.5%. The rate in our center is lower than that in other centers [10, 11] and was in line with the studies of the People's Republic of China. [12] The risk of developing malignancy after renal transplantation is due to exposure to immunosuppressive drugs in higher doses and longer periods due to acute or chronic rejection, exposure to viruses known to be carcinogenic, and the presence of direct carcinogenic immunosuppressive genes. [13] The incidence of hepatic carcinoma after kidney transplant may be associated with higher incidence of hepatitis B. There was one case of hepatic carcinoma in our center, and it was related with hepatitis B.
Each transplant center varies obviously with regard to the predilection sites and types of post-operative malignancy of renal transplantation. The most common malignancies in solid organ transplantation are skin and lip carcinoma, followed by lymphoma, Kaposi's sarcoma, cervical carcinoma, renal carcinoma, vulva and perineal carcinoma, hepatic carcinoma, and other malignancies. [14] Similar types of cancer were detected in our study, consistent with previous studies.
Renal carcinoma is more common in patients with acquired kidney cysts. [15] The patient who developed renal carcinoma in the post-transplantation period was neither polycystic kidney disease nor suspicious cyst and mass in pretransplant examination.
Increased dosing of immunosuppressive drugs can lead to the risk of developing cancer. Therefore, the dosage of immunosuppressive drugs should be as low as possible so that patients do not experience rejection, but it is hard to achieve balance between rejection and toxicity. [12] In this single-center study, the number of patients was insufficient to make clear statements. However, similar with other studies, cancer incidence and cancer types were encountered. [5, [9] [10] [11] [12] In our cancer-developing patients, immunosuppressive drugs were carefully reduced after the cancer operation. We observed no deaths caused by malignity.
Every patient with renal transplantation should be followed up carefully by regular physical examination, laboratory findings, and imaging studies due to the risk of malignancy. Regular imaging of the native kidney, not only the transplant kidney, should be neglected for renal carcinoma. Early diagnosis of malignancy is essential to preserve the benefits of transplantation in both patient survival and functional renal graft.
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